Hemato Oncology Testing Market Size, Share & Growth Report 2032

Hemato Oncology Testing Market Report Scope & Overview:

Hemato Oncology Testing Market was valued at USD 3.32 billion in 2023 and is expected to reach USD 10.49 billion by 2032, growing at a CAGR of 13.67% from 2024-2032.

The Hemato Oncology Testing Market report provides novel insights through an in-depth analysis of global hematologic cancer incidence and prevalence in 2023, highlighting regional differences and disease burden. The report analyzes trends in hemato-oncology testing adoption, which illuminates changing clinical practices. The report also examines market trends in NGS and PCR-based testing, identifying technological developments and inclinations. Moreover, it analyzes the reimbursement environment and regulatory changes impacting accessibility. A comprehensive cost analysis and healthcare expenditure review for 2023 is provided, along with insights into the growth of precision medicine and companion diagnostics, driving personalized treatment strategies in hemato-oncology.

The U.S. leads the North American Hemato Oncology Testing Market with 13.96% CAGR because of its high incidence of hematologic cancers, developed healthcare infrastructure, and robust uptake of precision medicine. Favorable reimbursement policies, wide research funding, and the presence of key market players further bolster its dominance in the region.

Market Dynamics

Drivers

The growing prevalence of hematologic cancers like leukemia, lymphoma, and myeloma is one of the key drivers for the Hemato Oncology Testing Market.

As per the Leukemia & Lymphoma Society, in 2023, blood cancers were responsible for about 10% of all new cancer diagnoses in the U.S. alone. The growing global incidence of these conditions has spurred the demand for early and precise diagnostic tools. Sophisticated technologies like Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and Fluorescence In Situ Hybridization (FISH) are increasingly being used to detect genetic mutations and direct targeted therapies. The latest example is the US FDA approval of QIAGEN's therascreen FGFR2 RGQ RT-PCR Kit to detect genetic mutations in leukemia, further endorsing the increasing importance of molecular diagnostics in hematologic cancer treatment.

Increasing Adoption of Precision Medicine and Companion Diagnostics is driving the market growth.

The move towards precision medicine has largely influenced the Hemato Oncology Testing Market by making it possible to have treatment methods tailored according to genetic profiles. Companion diagnostics are essential in determining the appropriate treatment for patients based on the molecular profile of their tumor. The U.S. FDA has approved over 50 companion diagnostic tests as of 2023, most of which target hematologic malignancies. For example, Illumina's TruSight Oncology 500 and Thermo Fisher Scientific's Oncomine Dx Target Test have been extensively used to identify several genetic mutations in blood cancers. With drug companies joining hands with diagnostic companies to come up with targeted treatments, molecular and genomic testing is likely to increase. The trend is also supplemented by government funding and initiatives for the inclusion of precision medicine in standard cancer treatment.

Restraint

High Cost of hemato-oncology testing and Limited Reimbursement Policies are restraining the market growth.

One of the key constraints in the Hemato Oncology Testing Market is the high cost of advanced molecular and genetic testing, which hinders access, especially in low- and middle-income nations. Next-Generation Sequencing (NGS) and Multiplex PCR are costly technologies, whereby a single test will cost between $1,000 and $5,000, subject to the complexity and location. In addition, inconsistent reimbursement policies drive patients and healthcare providers to incur hefty expenses. For instance, though Medicare and U.S. private insurance companies pay for some molecular diagnostic tests, most targeted panels and full-sequencing assays are partially or not reimbursed. The situation is even worse in the emerging markets where the budgets in the healthcare sector are tight. Insufficient insurance coverage and substantial out-of-pocket payments can slow down market growth by discouraging the adoption of sophisticated hemato-oncology diagnostics.

Opportunities

The emergence of liquid biopsy technologies presents a significant opportunity for the Hemato Oncology Testing Market.

The development of liquid biopsy technologies holds huge potential for the Hemato Oncology Testing Market in the form of a less painful and more convenient alternative to conventional tissue biopsies. Liquid biopsies make it possible to identify circulating tumor DNA (ctDNA), cell-free RNA (cfRNA), and circulating tumor cells (CTCs) through an easy blood draw, enabling early diagnosis, monitoring of the disease, and evaluation of treatment response. This technology is especially useful for hematologic cancers such as leukemia and lymphoma, in which it is difficult to take bone marrow or lymph node biopsies. Guardant Health and Foundation Medicine are both expanding their liquid biopsy platforms to hematologic malignancies. The rise in adoption of NGS-based liquid biopsy panels and increasing investments in non-invasive diagnostic platforms are anticipated to fuel innovation and market growth in the forecast years.

Challenges

One of the biggest challenges in the Hemato Oncology Testing Market is the absence of standardization between testing methods and the intricate regulatory environment.

Laboratories and diagnostic firms employ different protocols for NGS, PCR, and flow cytometry-based tests, resulting in inconsistencies in test reliability and interpretation of results. Regulatory bodies such as the FDA, EMA, and China's NMPA are strict in guidelines for test validation, approval, and clinical usefulness, and meeting their requirements is time-consuming and expensive. Also, laboratory-developed tests (LDTs) are beset with regulatory uncertainties, since each country applies a different degree of regulation. In emerging economies, the absence of harmonized quality standards and accreditation requirements also hinders market expansion. These standardization and regulation issues slow product approval and restrict global market entry, acting as a hindrance to the large-scale implementation of cutting-edge hemato-oncology testing solutions.

Segmentation Analysis

By Cancer Type

The Lymphoma segment dominated the Hemato Oncology Testing Market with 45.28% market share in 2023 because of its high global prevalence, multiple subtypes, and growing demand for precision diagnosis. Lymphomas, both Hodgkin's lymphoma and non-Hodgkin lymphoma (NHL), are two of the most frequently diagnosed hematological malignancies, with NHL alone responsible for more than 500,000 new diagnoses globally in 2023. Their complexity necessitates sophisticated molecular testing methods, like NGS, PCR, and IHC, to identify genetic mutations, prognostic indicators, and therapeutic avenues. Moreover, the popularity of targeted drugs such as CAR-T cell therapy (e.g., Yescarta and Kymriah) has accelerated the need for companion diagnostics. Growing disease awareness, enhanced access to screening for hematologic cancer, and growing clinical research on lymphoma biomarkers strengthened its position as market leader even more.

By Product

The Services segment dominated the hemato-oncology testing market with 60.14% market share in 2023 because of the increasing demand for outsourced diagnostic tests, the growth in liquid biopsy methods, and the proliferation of precision medicine programs. Most hospitals and research centers do not have molecular testing capabilities within their organizations; thus the growing outsourcing of hematologic cancer diagnosis to specialty laboratories. Players such as Invitae, QIAGEN, and Labcorp provide full-service hematologic oncology testing services, comprising NGS-based panels, PCR-based tests, and flow cytometry analysis. Moreover, the expansion of companion diagnostics for targeted treatments has fueled demand for contract-based and customized testing services. Driven by increasing regulatory endorsement of precision oncology and increased clinical trial activity, service providers in the diagnostics segment have established a competitive advantage, leading to this segment's market leadership in 2023.

By Technology

The Polymerase Chain Reaction dominated the Hemato Oncology Testing Market with 32.14% market share in 2023 because of its sensitivity, cost-effectiveness, and popularity in the detection of hematologic malignancies. PCR is still considered the gold standard for the identification of genetic mutations, fusion genes, and minimal residual disease (MRD) in leukemia and lymphoma patients. Its speed of reporting and capacity to detect low-abundance mutations make it essential in the diagnosis of hematologic cancers. Major industry players like QIAGEN, Bio-Rad Laboratories, and Thermo Fisher Scientific provide specific PCR-based tests like the Therascreen JAK2 RGQ PCR Kit and QXDx BCR-ABL% %IS Kit. Besides, regulatory clearances and reimbursement incentives for PCR-based companion diagnostics further entrenched its use in clinical environments. Increasing demand for real-time and digital PCR technologies has also made PCR even more dominant in the market.

By End-Use

The Hospitals segment dominated the hemato-oncology testing market with a 74.55% market share in 2023 because it is the leading site of diagnosis and treatment for hematologic cancers like leukemia, lymphoma, and myeloproliferative neoplasms. Hospitals have sophisticated diagnostic labs, fully equipped pathology labs, and multidisciplinary oncology units to provide precise and prompt hematologic cancer testing. The presence of end-to-end testing solutions, such as PCR, NGS, and flow cytometry-based assays, enables hospitals to deliver accurate molecular profiling and customized treatment regimens. Hospitals also tend to partner with research organizations and pharmaceutical firms for clinical trials and companion diagnostics, fueling increased testing volumes. The growing use of automation, digital pathology, and AI-based diagnostics in hospital laboratories has further enhanced efficiency, supporting hospitals' stronghold in the world Hemato Oncology Testing Market.

Regional Analysis

North America dominated the hemato-oncology testing market with a 38.24% market share in 2023 because of its established healthcare infrastructure, high incidence of hematologic malignancies, and robust adoption of sophisticated diagnostic technologies. The region is favored by large-scale research activities, high government funding, and the presence of dominant market players spearheading innovation in hematologic cancer testing. Also, the presence of reimbursement policies and regulatory backing for precision medicine has spurred the uptake of next-generation sequencing (NGS) and polymerase chain reaction (PCR)-based tests. The U.S. is particularly at the forefront with its extensive use of companion diagnostics and a high number of clinical trials for targeted therapies.

Asia Pacific is the fastest-growing region of the Hemato Oncology Testing Market with 14.30% CAGR throughout the forecast period, influenced by growing cancer rates, expanded healthcare spending, and enhanced cancer diagnosis awareness. China, India, and Japan are highly investing in precision medicine and genomic analysis, resulting in a higher level of adoption of high-end testing technology. The area is also experiencing widespread development of healthcare facilities and enhanced access to molecular diagnostics as a result of government efforts. Moreover, the growing presence of foreign market participants and partnerships with domestic laboratories are improving the availability of innovative hematologic cancer testing solutions, further driving market expansion.

Key Market Players

F. Hoffmann-La Roche Ltd (Cobas BRAF V600 Mutation Test, Cobas EGFR Mutation Test)
Abbott Laboratories (Vysis EGR1 FISH Probe Kit, Vysis LSI BCR/ABL Dual Color, Dual Fusion Translocation Probe)
QIAGEN N.V. (Therascreen JAK2 RGQ PCR Kit, Therascreen PIK3CA RGQ PCR Kit)
Thermo Fisher Scientific Inc. (Oncomine Myeloid Research Assay, Ion Torrent Genexus System)
Illumina Inc. (TruSight Myeloid Sequencing Panel, NovaSeq 6000 System)
Bio-Rad Laboratories, Inc. (QXDx BCR-ABL% %IS Kit, Droplet Digital PCR System)
Cepheid (Xpert BCR-ABL Ultra, GeneXpert System)
EntroGen, Inc. (LeukoStrat CDx FLT3 Mutation Assay, BCR-ABL1 Quant RT-PCR Kit)
Asuragen, Inc. (QuantideX qPCR BCR-ABL IS Kit, AmplideX PCR/CE SMN1 Kit)
Invivoscribe, Inc. (LeukoStrat CDx FLT3 Mutation Assay, LymphoTrack Assays)
Adaptive Biotechnologies (clonoSEQ Assay, immunoSEQ Assay)
Amoy Diagnostics Co., Ltd. (AmoyDx FLT3 Mutation Detection Kit, AmoyDx BRAF V600 Mutation Detection Kit)
ARUP Laboratories (JAK2 V617F Mutation Detection by PCR, BCR-ABL1 Quantitative PCR)
MolecularMD (a subsidiary of ICON plc) (BCR-ABL Mutation Analysis, JAK2 V617F Mutation Analysis)
Beckman Coulter, Inc. (Navios EX Flow Cytometer, CytoFLEX Flow Cytometer)
Sysmex Corporation (XN-Series Hematology Analyzers, DI-60 Automated Digital Cell Morphology Analyzer)
Danaher Corporation (Leica Bond III Automated IHC/ISH Stainer, Cepheid GeneXpert System)
Invitae Corporation (Invitae Hereditary Hematologic Malignancies Panel, Invitae Myeloid Malignancies Panel)
ArcherDX, Inc. (Archer FusionPlex Myeloid Panel, Archer VariantPlex Core Myeloid Panel)
Vela Diagnostics (Sentosa SQ Leukemia Panel, Sentosa SX101 Instrument)

Suppliers (These suppliers provide critical components such as reagents, assay kits, nucleic acid extraction solutions, and sequencing consumables essential for hemato-oncology testing.)

Merck KGaA
Thermo Fisher Scientific
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
Roche Diagnostics
PerkinElmer, Inc.
QIAGEN N.V.
Beckman Coulter, Inc.
LGC Biosearch Technologies
Promega Corporation

Recent Development

March 2023 – Servier has entered into a strategic collaboration with QIAGEN to create a companion diagnostic test for the identification of IDH1 mutations. The test will be used in conjunction with Servier's current and pipeline targeted therapies for Acute Myeloid Leukemia (AML), to improve accuracy in treatment choice and patient response.
May 2024 – Jane Li, Senior Director of Oncology, Pharma, and CRO Partnerships for Clinical Sequencing at Thermo Fisher Scientific, underscored the importance of diagnostics in oncology. She pointed out that accurate and timely diagnostics are not only crucial to identifying a patient's disease state but also to informing the best treatment approaches, ultimately enhancing patient survival and care.

**Hemato Oncology Testing Market Report Scope**
Report Attributes	Details
Market Size in 2023	US$ 3.32 billion
Market Size by 2032	US$ 10.49 billion
CAGR	CAGR of 13.67% From 2024 to 2032
Base Year	2023
Forecast Period	2024-2032
Historical Data	2020-2022
Report Scope & Coverage	Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments	• By Cancer Type (Leukemia, Lymphoma, Myeloproliferative Neoplasms, Other Cancers) • By Product (Assay Kits and Reagents, Services) • By Technology (PCR, IHC, NGS, Cytogenetics, Other Technologies) • By End-Use (Hospitals, Academic & Research Institutes, Others)
Regional Analysis/Coverage	North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America)
Company Profiles	F. Hoffmann-La Roche Ltd, Abbott Laboratories, QIAGEN N.V., Thermo Fisher Scientific Inc., Illumina Inc., Bio-Rad Laboratories, Inc., Cepheid, EntroGen, Inc., Asuragen, Inc., Invivoscribe, Inc., Adaptive Biotechnologies, Amoy Diagnostics Co., Ltd., ARUP Laboratories, MolecularMD (a subsidiary of ICON plc), Beckman Coulter, Inc., Sysmex Corporation, Danaher Corporation, Invitae Corporation, ArcherDX, Inc., Vela Diagnostics, and other players.

Frequently Asked Questions

What is the expected CAGR in the Hemato Oncology Testing Market during 2024-2032?

Ans: The Hemato Oncology Testing Market is expected to grow at a CAGR of 13.67% from 2024-2032.

What is the market size of the Hemato Oncology Testing Market?

Ans: The Hemato Oncology Testing Market was USD 3.32 billion in 2023 and is expected to reach USD 10.49 billion by 2032.

What are the key drivers of the Hemato Oncology Testing Market?

Ans: Increasing Adoption of Precision Medicine and Companion Diagnostics is driving the market growth.

Which segment (By Product) dominated the projected years for the Hemato Oncology Testing Market?

Ans: The “Assay Kits and Reagents” segment dominated the Hemato Oncology Testing Market.

Which region dominated the Hemato Oncology Testing Market in 2023?

Ans: North America dominated the Hemato Oncology Testing Market in 2023.

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Primary Research

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3^rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Data Bank Validation

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.

Key Segments:

By Cancer Type

- Leukemia
  - Acute Myeloid Leukemia (AML)
  - Acute Lymphocytic Leukemia (ALL)
  - Chronic Lymphocytic Leukemia
  - Chronic Myeloid Leukemia
- Lymphoma
  - Non-Hodgkin Lymphoma
  - Hodgkin Lymphoma
- Myeloproliferative Neoplasms
  - Polycythemia vera (PV)
  - Essential thrombocythemia (ET)
  - Myelofibrosis (MF)
- Other Cancers

By Product

- Assay Kits and Reagents
- Services

By Technology

- PCR
  - Real-time qPCR
  - Digital PCR
- IHC
- NGS
- Cytogenetics
- Other Technologies

By End-Use

- Hospitals
- Academic & Research Institutes
- Others

Request for Segment Customization as per your Business Requirement: Segment Customization Request

Regional Coverage:

North America

US
Canada
Mexico

Europe

Eastern Europe
- Poland
- Romania
- Hungary
- Turkey
- Rest of Eastern Europe
Western Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Switzerland
- Austria
- Rest of Western Europe

Asia Pacific

China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific

Middle East & Africa

Middle East
- UAE
- Egypt
- Saudi Arabia
- Qatar
- Rest of Middle East
Africa
- Nigeria
- South Africa
- Rest of Africa

Latin America

Brazil
Argentina
Colombia
Rest of Latin America

Request for Country Level Research Report: Country Level Customization Request

Available Customization

With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:

Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players

Single User License 3350
~~5000~~ (33% Discount)
Enterprise User License 5350
~~8950~~ (40% Discount)
Excel Datasheet 2350
~~3050~~ (23% Discount)

Buy Now Request An Analyst Call

Hemato Oncology Testing Market Report Scope & Overview:

Market Dynamics

Segmentation Analysis

Regional Analysis

Key Market Players

Recent Development

Hemato Oncology Testing Market Report Scope

Frequently Asked Questions

Table of Contents:

Key Segments:

Regional Coverage:

Intra-abdominal Pressure Measurement Devices Market

Anti-Fungal Treatment Market

Colorectal Cancer Screening Market

Cell Therapy Human Raw Materials Market

Breast Cancer Therapeutics Market

Digital PCR-dPCR Market

Start a Conversation

Call Now

Call Now

Mail Us

Related Link

Quick Links

Payment Options

Hemato Oncology Testing Market Report Scope & Overview:

Market Dynamics

Segmentation Analysis

Regional Analysis

Key Market Players

Recent Development

Hemato Oncology Testing Market Report Scope

Frequently Asked Questions

Table of Contents:

Key Segments:

Regional Coverage:

Related Reports :

Intra-abdominal Pressure Measurement Devices Market

Anti-Fungal Treatment Market

Colorectal Cancer Screening Market

Cell Therapy Human Raw Materials Market

Breast Cancer Therapeutics Market

Digital PCR-dPCR Market

Subscribe Now to Our Weekly Newsletter!

Select any four category

Start a Conversation

Call Now

Call Now

Mail Us

Related Link

Quick Links

Payment Options

Cookies Consent